Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims: Metformin is the most widely used oral anti‐diabetes agent and has considerable benefits over other therapies, yet 20–30% of people develop gastrointestinal side effects, and 5% are unable to tolerate metformin due to the severity of these side effects. The mechanism for gastrointestinal side effects and their considerable inter‐individual variability is unclear. We have recently shown the association between organic cation transporter 1 (OCT 1) variants and severe intolerance to metformin in people with Type 2 diabetes. The aim of this study was to explore the association of OCT 1 reduced‐function polymorphisms with common metformin‐induced gastrointestinal side effects in Type 2 diabetes. Methods: This prospective observational cohort study included 92 patients with newly diagnosed Type 2 diabetes, incident users of metformin. Patients were genotyped for two common loss‐of‐function variants in the OCT 1 gene (SLC 22A1): R61C (rs12208357) and M420del (rs72552763). The association of OCT 1 reduced‐function alleles with gastrointestinal side effects was analysed using logistic regression. Results: Forty‐three patients (47%) experienced gastrointestinal adverse effects in the first 6 months of metformin treatment. Interestingly, the number of OCT 1 reduced‐function alleles was significantly associated with over two‐fold higher odds of the common metformin‐induced gastrointestinal side effects (odds ratio = 2.31, 95% confidence interval 1.07–5.01, P = 0.034). Conclusions: In conclusion, we showed for the first time the association between OCT 1 variants and common metformin‐induced gastrointestinal side effects. These results confirm recent findings related to the role of OCT 1 in severe metformin intolerance, and suggest that high inter‐individual variability in mild/moderate and severe gastrointestinal intolerance share a common underlying mechanism. These data could contribute to more personalized and safer metformin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Accumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418
Cited by
Daliri, E., Oh, D., & Lee, B. (2017) · Foods · doi:10.3390/foods6050032 · Cited by 539
Metformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414
Understanding and overcoming metformin gastrointestinal intolerance
Bonnet, F., & Scheen, A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12854 · Cited by 256
Shabbir, H., Kausar, T., Noreen, S., Rehman, H. U., Hussain, A., Huang, Q., Gani, A., Su, S., & Nawaz, A. (2020) · Animals · doi:10.3390/ani10091714 · Cited by 140
“Although, various drugs have been discovered in order to control diabetes, however, some have side effects [3]; thus, screenings of antidiabetic agents, especially the functional foods, are inevitable.”
BackgroundUsing probiotics for type 2 diabetes mellitus intervention: Advances, questions, and potential
Sun, Z., Sun, X., Li, J., Li, Z., Hu, Q., Li, L., Hao, X., Song, M., & Li, C. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1547268 · Cited by 117
Barengolts, E., Green, S. J., Eisenberg, Y., Akbar, A., Reddivari, B., Layden, B. T., Dugas, L., & Chlipala, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194171 · Cited by 111
The emerging role of metformin in gestational diabetes mellitus
Gray, S. G., McGuire, T. M., Cohen, N., & Little, P. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12893 · Cited by 40
MATE2 Expression Is Associated With Cancer Cell Response to Metformin
Chowdhury, S., Yung, E., Pintilie, M., Muaddi, H., Chaib, S., Yeung, M., Fusciello, M., Sykes, J., Pitcher, B., Hagenkort, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165214 · Cited by 33
Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder
Trujillo-Del Río, C., Tortajada-Pérez, J., Gómez-Escribano, A. P., Casterá, F., Peiró, C., Millán, J. M., Herrero, M. J., & Vázquez-Manrique, R. P. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111670 · Cited by 19
Metadata
- Authors
- Dujic, T., Causevic, A., Bego, T., Malenica, M., Velija‐Asimi, Z., Pearson, E. R., & Semiz, S.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2015-12-24
- Volume
- 33
- Issue
- 4
- Pages
- 511-514
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2181174026
- Cited by
- 136
- References
- 3
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.